Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Insider and Institutional Ownership
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for Nektar Therapeutics and Cardiff Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 4 | 10 | 1 | 2.69 |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
Volatility and Risk
Nektar Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
Valuation & Earnings
This table compares Nektar Therapeutics and Cardiff Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nektar Therapeutics | $55.23 million | 24.63 | -$164.08 million | ($6.70) | -5.95 |
| Cardiff Oncology | $508,000.00 | 159.27 | -$45.85 million | ($0.60) | -1.73 |
Cardiff Oncology has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nektar Therapeutics and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
Summary
Nektar Therapeutics beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
